CDC NEWS


powered by Surfing Waves


Latest News


Covid Live Updates: Extra Dose of J. & J. Vaccine Raises Protection, Company Says


21 Sep 2021

In a clinical trial, researchers found that two doses of the vaccine delivered 94 percent efficacy against mild to severe Covid-19.


Breakthrough Infections in Vaccinated People Less Likely to Cause ‘Long COVID’


14 Sep 2021

There’s no question that vaccines are making a tremendous difference in protecting individuals and whole communities against infection and severe illness from SARS-CoV-2, the coronavirus that causes COVID-19. And now, there’s yet another reason to get the vaccine: in the event of a breakthrough infection, people who are fully vaccinated also are substantially less likely to develop Long COVID Syndrome, which causes brain fog, muscle pain, fatigue, and a constellation of other debilitating symptoms that can last for months after recovery from an initial infection.


COVID-19 Infected Many More Americans in 2020 than Official Tallies Show


07 Sep 2021

At the end of last year, you may recall hearing news reports that the number of COVID-19 cases in the United States had topped 20 million. While that number came as truly sobering news, it also likely was an underestimate. Many cases went undetected due to limited testing early in the year and a large number of infections that produced mild or no symptoms. Now, a recent article published in Nature offers a more-comprehensive estimate that puts the true number of infections by the end of 2020 at more than 100 million [1]. That’s equal to just under a third of the U.S. population of 328 million. This revised number shows just how rapidly this novel coronavirus spread through the country last year. It also brings home just how timely the vaccines have been—and continue to be in 2021—to protect our nation’s health in this time of the pandemic.


Vaccines prevented up to 140,000 COVID-19 deaths in U.S.


24 Aug 2021

Three highly effective COVID-19 vaccines are available in the U.S. These vaccines have been shown to slow the spread of the virus and reduce COVID-19 deaths. About half of the population has been fully vaccinated as of August 2021. But vaccination rates have varied across the country, with some states proceeding much faster than others.


U.S. to Advise Boosters for Most Americans 8 Months After Vaccination


18 Aug 2021

The Biden administration has decided that most Americans should get a coronavirus booster vaccination eight months after they received their second shot, and could begin offering third shots as early as the third week of September, according to administration officials familiar with the discussions.




Articles


We are scheduling training with them this week on how to generate the report.


07 Jun 2021

The Centers for Disease Control and Prevention (CDC) recently issued guidance that fully vaccinated individuals can safely remove masks and end social distancing in most indoor settings.1 Educational facilities and businesses are faced with whether and how to differentiate between vaccinated and unvaccinated individuals, including requiring proof of vaccination. Mandatory vaccination has historically served as a tool to reach and sustain high immunization coverage and to prevent transmission in K-12 schools, colleges/universities, and health care facilities. Vaccine mandates could extend to workers and customers in businesses to ensure safer environments. This Viewpoint examines the epidemiologic, public health, and legal considerations for mandatory SARS-CoV-2 vaccinations in each setting.




Mix-and-match COVID vaccines trigger potent immune response


19 May 2021

Preliminary results from a trial of more than 600 people are the first to show the benefits of combining different vaccines.




Even Partial COVID-19 Vaccination Protects Nursing Home Residents


17 May 2021

A CDC analysis has shown that a single dose of the Pfizer-BioNTech COVID-19 vaccine protected medically vulnerable nursing home residents as well as it did general adult populations that were evaluated in other efficacy and effectiveness studies.




Delayed Localized Hypersensitivity Reactions to the Moderna COVID-19 Vaccine


12 May 2021

The Moderna COVID-19 vaccine may cause a delayed localized hypersensitivity reaction with a median latency to onset of 7 days after vaccine administration. This pruritic and variably tender reaction has a median duration of 5 days, but may persist for up to 21 days, and may occur again and sooner after the second vaccine dose; no serious adverse events were observed in association with this cutaneous reaction to the Moderna COVID-19 vaccine.




The epidemiological impact of the NHS COVID-19 App


12 May 2021

The COVID-19 pandemic has seen digital contact tracing emerge around the world to help prevent spread of the disease. A mobile phone app records proximity events between app users, and when a user tests positive for COVID-19, their recent contacts can be notified instantly. Theoretical evidence has supported this new public health intervention1-6, but its epidemiological impact has remained uncertain7. Here we investigated the impact of the NHS COVID-19 app for England and Wales, from its launch on 24 September 2020 through to the end of December 2020. It was used regularly by approximately 16.5 million users (28% of the total population), and sent approximately 1.7 million exposure notifications: 4.4 per index case consenting to contact tracing. We estimated that the fraction of app-notified individuals subsequently showing symptoms and testing positive (the secondary attack rate, SAR) was 6.0%, comparable to the SAR for manually traced close contacts. We estimated the number of cases averted by the app using two complementary approaches. Modelling based on the notifications and SAR gave 284,000 (108,000-450,000), and statistical comparison of matched neighbouring local authorities gave 594,000 (317,000-914,000). Roughly one case was averted for each case consenting to notification of their contacts. We estimated that for every percentage point increase in app users, the number of cases can be reduced by 0.8% (modelling) or 2.3% (statistical analysis). These findings provide evidence for continued development and deployment of such apps in populations that are awaiting full protection from vaccines.




Enroll for Free